Retro Biosciences, a biotech startup that wants to extend the human lifespan by 10 years, is raising $1 billion in a Series A funding round. OpenAI CEO Sam Altman, who earlier gave $180 million to the startup in seed funding, is joining the round, the FT reported. The startup plans to initiate drug trials targeting diseases like Alzheimer's.